Pharmaron Beijing Co., Ltd. Class A · SZSE:300759
Pharmaron Beijing Co., Ltd. Class A — H1 2022 Earnings Presentation
26 slides from Pharmaron Beijing Co., Ltd. Class A's earnings presentation, August 2022
Slide 1: 2022 Interim Results Announcement
Stock code：300759.SZ Stock code：3759.HK 2022 Interim Results Announcement August, 2022
Slide 2: Disclaimer
Disclaimer The documents, opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Com
Slide 3: Performance Overview, Business Highlights, Financial Highlights, Growth Strategy
Performance Business Financial Growth Overview Highlights Highlights Strategy
Slide 4: Content: Performance Overview
01 02 03 04 CONTENT Performance Business Financial Growth Overview Highlights Highlights Strategy
Slide 5: 2022H1 Performance Overview
2022H1 Performance Overview Revenue (RMB mm) 2,000+ 7,443.8 Over 90% of revenue 5,133.6 Customers served(1） From repeat customers 3,757.2 4,634.6 2,908.1 3,285.5 2,294.1 400+ 14.4% New Customers Addition TOP20 global pharmaceutical 2017 2018 2019 2020 2021 2021H1 2022H1 companies contributed Gross P
Slide 6: Global Footprint
Global Footprint 9 6 5 China U.S. U.K. Beijing HQ Ningbo Shanghai Baltimore, MD Germantown, MD Cardiff Hoddesdon Laboratory services Laboratory services Laboratory services Clinical development Clinical development Radiolabelled Sicience Discovery & Early CMC 1.2 million ft2 2.56 million ft2 130,000
Slide 7: ESG: Promote sustainable development actively
ESG Promote sustainable development actively Launched the Science Based Targets 2021-2025 Environmental Targets Initiative (SBTi) SBTi Commitment Letter /per RMB10,000 of output value Promote the decarbonization transformation of its supply chain and scientifically achieve the emission reduction and
Slide 8: Content: Business Highlights
01 02 03 04 CONTENT Performance Business Financial Growth Overview Highlights Highlights Strategy
Slide 9: 2022H1 Business Segment Highlights
2022H1 Business Segment Highlights ◼ We operate our leading fully-integrated pharmaceutical R&D services platform through four main business segments, namely, Laboratory Services, CMC (Small Molecule CDMO) Services, Clinical Development Services and Biologics and CGT Services, in China, the U.S. and
Slide 10: Laboratory Services
Ⅰ Laboratory Services Maintain world leading position in laboratory chemistry，accelerate the growth in Bioscience and strengthen the global network ◼ Revenue 2,860.1 1,542.9 ◼ Participating in 576 drug discovery projects and 52 IND or NDA filings, 2,027.0 of which, 48 projects applied with multiple
Slide 11: Laboratory Services: Infrastructure and M&A Expansion
Ⅰ Laboratory Services ◼ Infrastructure construction： ➢ Phase II of the Ningbo Campus I, Remaining 42,000㎡ laboratory space was in the process of internal installation , part of them were gradually in operation. ➢ Commenced the construction of 140,000㎡ safety assessment and in vivo bioscience facilit
Slide 12: CMC (Small Molecule CDMO) Services
Ⅱ CMC (Small Molecule CDMO) Services Maintain core competent on early-stage project, expand to late and commercial stage manufacturing services with our service networks in China, US and UK ◼ Revenue ◼ With the seamless integration of the Company’s fully-integrated R&D 623.1 service platform, ~76% o
Slide 13: CMC Services: Infrastructure and M&A Expansion
Ⅱ CMC (Small Molecule CDMO) Services ◼ Infrastructure construction： ➢ Reactor volume of 200m³ of Shaoxing Plant Phase1 was operational in early 2022 and the remaining reactor volume of 400m³ are expected to be put into use in the second half of 2022. Internal and M&A ◼ M&A expansion Expansion ➢ Acqu
Slide 14: Clinical Development Services
Ⅲ Clinical Development Services Fully-integrated clinical development services in China, assist domestic customers to launch their program abroad with our overseas service capabilities ◼ Revenue 319.2 ◼ The on-site management team works with more than 600 hospitals and clinical 584.5 trial centers a
Slide 15: Clinical Development Services Platform
Ⅲ Clinical Development Services Pharmaron Clinical Internal and Services M&A Platform in Expansion China Chengdu, China 客户构成 Baltimore, US Rushden,UK Source: 2022 Interim Report，As of June 30, 2022
Slide 16: Biologics and CGT Services
Ⅳ Biologics and CGT Services Establish world-leading end-to-end CGT services platform, continue to build the services capabilities in Biologics development and manufacturing ◼ Revenue ◼ Company has > 50 programs at various stages for analytical release testing, including Operational 19 potency assay
Slide 17: Biologics and CGT: Internal and M&A Expansion
Ⅳ Biologics and CGT Services Internal and Biologics CDMO in Ningbo M&A Expansion Gene Therapy CDMO in Liverpool 客户构成 CGT Laboratory Services in the US Source: 2022 Interim Report，As of June 30, 2022
Slide 18: Content: Financial Highlights
01 02 03 04 CONTENT Performance Business Financial Growth Overview Highlights Highlights Strategy
Slide 19: 2022H1 Financial Performance
2022H1 Financial Performance Revenue RMB mm 2.1% 0.2% 12.1% 4,634.6 12.6% +41.1% Laboratory Services China Entities CMC (small molecule CDMO) Services 3,285.5 23.4% Overseas subsidiaries Clinical Development Services 61.7% Biologics and CGT Services 87.9% Other 2021H1 2022H1 Net Cash Flows Generated
Slide 20: 2022H1 Non-IFRS adjusted net profit attributable to owners of the parent
2022H1 Non-IFRS adjusted net profit attributable to owners of the parent RMB mm 2021H1 2022H1 Margin 19.8% 17.5% Profit attributable to owners of the parent 564.8 585.4 812.1 +24.7% Add: 651.4 Share-based compensation expenses 21.9 42.6 Convertible Bonds related gains or losses 106.8 65.5 Foreign ex
Slide 21: 2022H1 Expenses for the Period
2022H1 Expenses for the Period ◼ Administrative expenses as % of Total Revenue: During the reporting period, the Company completed several overseas acquisitions. With the relatively low revenue in the integration stage, the administrative expenses as % of total revenue increased. ◼ Net finance costs
Slide 22: Working Capital Management Capabilities
Working Capital Management Capabilities Trade Receivables and Contract Assets Turnover(1) Trade Payables Turnover(2) Days Days 23.3 78.5 77.7 19.1 65.6 66.2 16.8 17.3 2019 2020 2021 2022H1 2019 2020 2021 2022H1 Inventories Turnover(2) Contract Costs Turnover(2) Days Days 13.9 12.4 12.6 11.9 12.0 11.
Slide 23: Capital Expenditure, Cash, Bank Facilities and Liabilities
Capital Expenditure, Cash, Bank Facilities and Liabilities Capital Expenditure note1 Cash, Bank Facilities and Liabilities note 2 RMB mm 6,998.7 RMB mm 3,853.6 6,480.8 3,529.8 5,757.1 5,386.7 5,367.8 5,003.0 2,416.1 3,000 972.3 844.4 781.0 2019 2020 2021 2022H1 2019 2020 2021 2022H1 Cash and Cash Eq
Slide 24: Content: Growth Strategy
01 02 03 04 CONTENT Performance Business Financial Growth Overview Highlights Highlights Strategy
Slide 25: Our Growth Strategies
Our Growth Strategies ◼ Continue to build and improve our “end-to-end, fully integrated and global” pharmaceutical R&D service platform ◼ Continue to strengthen the short and medium terms revenue and profit generating services and actively develop new services capabilities for the long term Continue
Slide 26: Thank you
Thank you